Breast cancer is the leading type of cancer diagnosed in women worldwide and require predictive research modes for preclinical drug development. Patient Derived Xenograft (PDX) models provide a true representation of the human heterogeneity and can be used to test the efficacy of novel agents against drug resistance. The CrownBio breast cancer PDX collection consists of a wide range of models, including 17 Triple negative breast cancer lines as well as ER+, PR+, and HER2+ models. More
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.